The COVID-19 pandemic has highlighted the vulnerability of pharmaceutical supply chains. Lockdowns and border closures left several pharmaceutical companies with limited access to key raw materials.

GlobalData has conducted a survey to assess how pharmaceutical companies are addressing and monitoring import/export and supply chain risks associated with coronavirus.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The respondent companies were broadly classified into three categories – companies without marketed drugs, companies with predominantly marketed drugs​, and companies with both pipeline and marketed drugs.

A majority 50% of the companies with both pipeline and marketed drugs opined that they do not have a dedicated team to address the risks, but they have committees/working teams that meet up regularly. Whereas 39% of the companies had a dedicated team and 11% depended on suppliers to identify the risks.

Among companies without marketed drugs, 47% depended on suppliers to identify the risks and 33% did not have a dedicated team to address the risks, while 20% had a dedicated team.

Import-export and supply chain risks

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Monitoring of import/export risks by company type​

Approximately 36% of companies with both pipeline and marketed drugs had a dedicated team to manage the risks, while another 36% did not have a dedicated team and the remaining depended on suppliers to identify the risks.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.